Strength, hypertrophy, power, endurance, recovery and training adaptation overlap—but they are not interchangeable outcomes. This category is full of claims built from hormonal activity, mitochondrial biology and recovery signals that may or may not translate into better human performance.
Raising a hormone, changing a biomarker or influencing a pathway can be biologically meaningful without proving faster, stronger or more durable performance.
The cleanest way to evaluate a performance claim is to ask what was actually measured—and whether that measurement matters in the real world.
The performance conversation mixes together GH-axis compounds, mitochondrial peptides and recovery-oriented molecules. Their evidence maturity—and the outcomes actually studied—vary widely.
A growth hormone-releasing factor analog with an FDA-approved indication for reducing excess abdominal fat in adults with HIV-associated lipodystrophy.
A GHRH(1-29) analog that stimulates endogenous growth hormone release and is used clinically in some compounded settings.
A selective ghrelin-receptor agonist studied for growth-hormone release and gastrointestinal motility, with limited evidence for common biohacking claims.
A long-acting GHRH analog designed to increase growth hormone and IGF-1 exposure; clinical development remained limited.
A ghrelin-receptor agonist and growth-hormone secretagogue studied in humans, but not approved in the U.S. for wellness or performance.
A growth-hormone secretagogue that also strongly engages appetite signaling through the ghrelin receptor.
A potent growth-hormone secretagogue studied in endocrine and cardiovascular research settings.
A mitochondrial-derived peptide studied for metabolic signaling, exercise adaptation and aging biology; human evidence remains early.
A mitochondria-targeting tetrapeptide studied in multiple human clinical programs, making it more clinically developed than many biohacking peptides.
Evidence scores are editorial orientation, not performance rankings. A compound can have documented hormonal activity without established benefits for strength, hypertrophy or athletic performance.
The appeal is easy to understand: growth-hormone signaling sounds anabolic, mitochondrial biology sounds energizing, and recovery compounds sound like a shortcut to more training. The evidence is much less uniform than the narrative.
The strongest performance system is usually built from training, recovery, nutrition and measurement—not a single molecule.
Future coverage can follow resistance training, protein intake, creatine, sleep, periodization, VO₂ testing, body-composition measurement, rehabilitation, wearables and emerging performance therapeutics.
Real human evidence and an approved indication—without proving general-purpose muscle or performance enhancement.
Human biology is compelling, but endogenous signaling should not be confused with proven exogenous performance benefits.
Real human evidence and FDA approval in a rare disease context do not validate broad performance claims in healthy people.
Compare Human Evidence, Community Signal, The Gap and regulatory status across the broader library.